Remove Biosimilars Remove Pharmaceutical Companies Remove Pharmaceutical Manufacturing
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

2) limiting the scope and number of patents asserted in litigation against proposed biosimilar entrants. 3) policing anticompetitive settlements between competing drug manufacturers. 4) prohibiting ‘product hopping’ and interference with generic and biosimilar substitutions. 5) monitoring access to biosimilars.

article thumbnail

ACI To Host Multiple Events Featuring HP&M Speakers – Discounts Available to FDA Law Blog Readers

FDA Law Blog: Biosimilars

His practice supports clients throughout the life sciences from biotech startups and multinational pharmaceutical companies to CROs and academic researchers to patient advocacy organizations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sustainability is more than a commitment, it’s a path to operational efficiency and long-term value creation

Express Pharma

With growing awareness of the environmental impact of pharmaceutical manufacturing—such as pollution from toxic discharges—companies must adopt more sustainable practices. One of the primary challenges the industry faces is the inherent resource intensity of pharmaceutical manufacturing.

article thumbnail

Exclusive Coverage: Global PHT Expo & Summit 2023

PharmaShots

The speakers shared their views on the topic: Dr. Jagadeesh Babu Rangisetty- “COVID has taught us so many things and the pharmaceutical company has gone through a lot of challenges and at the same time opportunities. According to me the main issue faced during the pandemic was the supply chain of pharmaceuticals.